The efficacy and safety of endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33926-33934

  Guan, Ying ^a,b   Li, Anchuan ^c   Xiao, Weiwei ^a   Liu, Shuai ^d   Chen, Binbin ^a   Lu, Taixiang ^a   Zhao, Chong ^a   Han, Fei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Guangxi Cancer Institute   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Endostar; Intensity modulated radiotherapy; Nasopharyngeal carcinoma; Recurrence

Indexed keywords

RECOMBINANT ENDOSTATIN; CISPLATIN; ENDOSTATIN; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MUCOSAL NECROSIS; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PHARYNX DISEASE; PHARYNX HEMORRHAGE; TREATMENT RESPONSE; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NASOPHARYNGEAL NEOPLASMS; PROCEDURES; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; ENDOSTATINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, INTENSITY-MODULATED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84946098704     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5271     Document Type: Article

References (26)

1. Han F, Zhao C, Huang SM, Lu LX, Huang Y, Deng XW, Mai WY, Teh BS, Butler EB, Lu TX. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol. 2012; 24:569-576.
2. Zou X, Han F, Ma WJ, Deng MQ, Jiang R, Guo L, Liu Q, Mai HQ, Hong MH, Chen MY. Salvage endoscopic nasopharyngectomy and intensity-modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma. Head Neck. 2014; Apr. doi: 10.1002/hed.23719.
3. Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong MH, Lu TX, Zhao C. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer. 2012; 48:3422-3428.
4. Tian YM, Tian YH, Zeng L, Liu S, Guan Y, Lu TX, Han F. Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy. Br J Cancer. 2014; Jan 110:297-303.
5. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005; 23:8646-8654.
6. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23:5578-5587.
7. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with paltinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23:5568-5577.
8. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25:2171-2177.
9. Li GH, Zhu B, Yang F, Ma CK, Yang DQ. Use of cetuximab in combination with pulsed reduced dose-rate radiotherpy in a patient recurrence of nasopharyngeal caricoma in the neck. Exp Ther Med. 2012; 3:869-872.
10. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007; 361:79-84.
11. Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, Chen J, Hu X, Zhou Q, Wang Y, Ma H, Bao Y, Chen M. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012; 7:e34646.
12. Sun Y, Wang JW, Liu Y, Song X, Zhang Y, Li K, Zhu Y, Zhou Y, Zhou Q, You L, Yao C. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small lung cancer (NSCLC) patients. J Clin Oncol. 2005; 23:7138.
13. Poon D, Yap SP, Wong ZW, Cheung YB, Leong SS, Wee J, Tan T, Fong KW, Chua ET, Tan EH. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys. 2004; 59:1312-1318.
14. Chua DT, Sham JS, Leung LH, Au GK. Reirradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol. 2005; 77:290-294.
15. Tian YM, Guan Y, Xiao WW, Zeng L, Liu S, Lu TX, Zhao C, Han F. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1-T2 nasopharyngeal carcinoma. Head Neck. 2014;. doi: 10.1002/hed.23880.
16. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005; 23:3568-3576.
17. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, KozloffMF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II. Lancet Oncol. 2009; 10:247-257.
18. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Sawides P, Romkes M. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011; 29:1140-1145.
19. Ye W, Liu R, Pan C, Jiang W, Zhang L, Guan Z, Wu J, Ying X, Li L, Li S, Tan W, Zeng M, Kang T, et al. Multicenter randomized phase II clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol Ther. 2014; 22:1221-1229.
20. Qiu S, Lin S, Tham IW, Pan J, Lu J, Lu JJ. Intensitymodulated radiation therapy in the salvage of recurrent nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys. 2012; 83:676-683.
21. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9:453-461.
22. Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res. 2001; 61:3348-3354.
23. Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res. 2004; 10:3342-3353.
24. Chen MY, Mai HQ, Sun R, Guo X, Zhao C, Hong MH, Hua YJ. Clinical findings and imaging features of 67 nasopharyngeal carcinoma patients with postradiation nasopharyngeal necrosis. Chin J Cancer. 2013; 32:533-538.
25. Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L. Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012; 6:309-315.
26. Chen J, Liu DG, Yang G, Kong LJ, Du YJ, Wang HY, Li FD, Pei FH, Song JT, Fan YJ, Liu AY, Wang XH, Li BX. Endostar, a novel human recombinant endostatin, attenuates liver fibrosis in CCl4-induced mice. Exp Biol Med (Maywood). 2014; 239:998-1006.